Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim

NCT00005958 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00005958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 1999
Completion date
Not reported
Enrollment
Not reported
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, transitional cell cancer of the renal pelvis and ureter